Investors & Media
What's new.
Press releases
Press releases.
March 23rd 2023
press releases
March 14th 2023
press releases
February 6th 2023
press releases
Investor updates
Investor updates.
Analyst reports
Analyst reports.
Maxim Group - New P2/3 AIPAC-003 Study Initiated with More Aggressive Dosing and OS Primary in Breast Cancer; Rating Buy, $8 tgt (Analyst: Jason McCarthy, PhD)
March 14th 2023
analyst reports
CLSA - Immutep: Defining year. Cash-runway through late stage head & neck readout and Lung Ph3 start. Retain Buy, A$1.25 tgt (Andrew Paine)
March 7th 2023
analyst reports
Petra Capital - Immutep Limited (IMM) - Accelerating clinical and manufacturing work (Analyst: Tanushree Jain)
February 28th 2023
analyst reports